2025 ESC Guidelines for the management of myocarditis and pericarditis
This guideline cites 7 of the 199 landmark trials in our Cardiology register.
- Issued by
- ESC
- Year
- 2025
- Source
- Schulz-Menger J, Bauersachs J, et al. Eur Heart J. 2025;46(40):3952–4041.doi 10.1093/eurheartj/ehaf192
The first ESC guideline to cover myocarditis and pericarditis together. It cements colchicine as first-line adjunctive therapy from the very first attack of pericarditis, escalates to interleukin-1 blockade in colchicine-resistant, corticosteroid-dependent recurrence, and defines a biopsy-guided pathway for virus-negative inflammatory cardiomyopathy. The register's trials are grouped by that treatment ladder below.
Acute pericarditis: colchicine1
- 2013ICAP CoreCardiology · Inflammatory · Acute pericarditisIn 240 patients with a first episode of acute pericarditis, colchicine added to conventional anti-inflammatory therapy reduced incessant or recurrent pericarditis compared with placebo.16.7% vs 37.5%Read →
Recurrent pericarditis: colchicine & IL-1 blockade4
- 2021RHAPSODYCardiology · Inflammatory · Recurrent pericarditisIn 86 patients with recurrent pericarditis and an elevated C-reactive protein level, continued weekly rilonacept prolonged time to first pericarditis recurrence compared with randomised withdrawal to placebo.HR 0.0495% CI 0.01-0.18Read →
- 2016AIRTRIPCardiology · Inflammatory · Recurrent pericarditisIn 21 patients with colchicine-resistant, corticosteroid-dependent recurrent pericarditis, continued anakinra markedly reduced recurrent pericarditis after randomised withdrawal compared with a switch to placebo.18.2% vs 90.0%Read →
- 2014CORP-2Cardiology · Inflammatory · Recurrent pericarditisIn 240 patients with at least two prior recurrences of pericarditis, colchicine for 6 months added to conventional anti-inflammatory therapy reduced further recurrent pericarditis compared with placebo.RR 0.4995% CI 0.24-0.65Read →
- 2011CORPCardiology · Inflammatory · Recurrent pericarditisIn 120 patients with a first recurrence of pericarditis, colchicine for 6 months added to conventional anti-inflammatory therapy halved further recurrence at 18 months compared with placebo.24% vs 55%Read →
Postpericardiotomy syndrome: prevention1
- 2014COPPS-2Cardiology · Inflammatory · Postpericardiotomy syndromeIn 360 patients scheduled for cardiac surgery, perioperative colchicine started before surgery and continued for 1 month reduced postpericardiotomy syndrome within 3 months compared with placebo, but did not prevent postoperative atrial fibrillation.19.4% vs 29.4%Read →
Myocarditis & inflammatory cardiomyopathy1
- 2009TIMICCardiology · Inflammatory · MyocarditisIn 85 patients with biopsy-proven virus-negative inflammatory cardiomyopathy and heart failure refractory to conventional therapy, 6 months of prednisone plus azathioprine improved left ventricular ejection fraction at 6 months compared with placebo.45.6% vs 21.3%Read →
Cited landmark trials not yet in the register4
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2010COPPS
The first colchicine trial for prevention of the postpericardiotomy syndrome.
- 2020CORP-2 open extension
Long-term colchicine exposure and relapse after withdrawal.
- 2022RHAPSODY long-term extension
Rilonacept withdrawal after 18 months and the risk of relapse.
- 2018MYOCARDITIS-CMR consensus cohorts
The Lake Louise criteria update that underpins CMR-based diagnosis without biopsy.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.